Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.RLU.0000057622.08265.54 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Retrospective study of post-treatment I SPECT/CT imaging for personalizing therapy of patients with differentiated thyroid cancer.
Folia Med (Plovdiv)
December 2024
Military Medical Academy, Sofia, Bulgaria.
The absence of anatomical landmarks in the whole body scan makes it challenging to precisely localize 131I uptake, which is used to treat patients with differentiated thyroid cancer (DTC). Recently, SPECT/CT studies have been utilized to increase the diagnostic sensitivity and specificity.
View Article and Find Full Text PDFPredictive factors influencing hypothyroidism following the radioactive iodine treatment of Graves' disease in different periods.
Sci Rep
December 2024
Department of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.
In China, due to the risks of hypothyroidism after radioiodine treatment, radioiodine is not commonly used as a first-line treatment. In this study, factors influencing the development of hypothyroidism after I therapy for Graves' hyperthyroidism were evaluated. This was a retrospective study with a 12-month follow-up.
View Article and Find Full Text PDFRadioactive Iodine Treatment for Thyroid Cancer Complicated by Lacrimal Sac Retention of Iodine.
JCEM Case Rep
January 2025
Division of Endocrinology, Medstar Georgetown University Hospital, Washington, DC 20007, USA.
Patients with intermediate-risk thyroid cancers may undergo treatment with radioactive iodine-131 (I-131). They often undergo a pretreatment diagnostic iodine scan that typically shows areas of physiological uptake in the stomach, bladder, parotid glands as well as thyroid-remnant uptake and sites of metastatic disease. A 48-year-old woman with intermediate-risk papillary thyroid cancer with metastases to lateral compartment lymph nodes was found to have increased retention of iodine in the medial portion of her left orbit on the diagnostic scan.
View Article and Find Full Text PDFSafety and toxicity of Iopofosine I 131 (CLR 131) with external beam radiation therapy in recurrent or metastatic head and neck cancer: results of a phase 1 single-centre, open-label, single-arm, dose escalation and dose expansion study.
EBioMedicine
January 2025
Department of Human Oncology, UW School of Medicine and Public Health, Madison, WI, USA.
Background: Re-irradiation of recurrent head and neck cancer (HNC) is often limited by tumour adherence to critical structures and/or radiation tolerance of critical normal tissues. Iopofosine I 131 (CLR 131) is a targeted small molecular phospholipid ether (PLE) drug conjugate that delivers iodine-131 selectively to tumour cells. We conducted a phase 1, single-centre, open-label study to determine whether CLR 131 given with reduced dose of external beam radiation therapy (EBRT) would be tolerable and feasible.
View Article and Find Full Text PDFIodine transfer to dairy cow's milk: A revised biokinetic model.
J Hazard Mater
December 2024
Faculty of Biosciences, Norwegian University of Life Sciences, PO Box 5003, Ås N-1432, Norway.
A new biokinetic model for iodine in dairy cows was developed utilizing data from a 4 × 4 factorial feeding experiment with rumen-cannulated cows that were fed rapeseed cake containing substances known to influence iodine metabolism, and soybean meal without such effects. I was administered both intravenously and intra-ruminally to document metabolism pathways. The new model included compartments such as saliva and thyroid gland, often ignored in other models, and in contrast to previously available biokinetic models, it fitted well to our experimental data.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!